Ocular Therapeutix reaches target enrollment of 555 patients in SOL-R trial
Author(s) : Martin David Harp Key Takeaways AXPAXLI is a bioresorbable hydrogel incorporating axitinib, targeting wet AMD and other retinal diseases with anti-angiogenic properties. The SOL-R trial compares AXPAXLI’s six-month dosing…